Latest news and articles about GLP-1 from NEX English
Lilly has announced that millions of Americans will have access to its new diabetes medications, with CVS pharmacy chain covering the costs of GLP-1 drugs like Foundayo and Zepbound. This development could significantly change the lives of many diabetes patients.
GLP-1 weight loss medications have gained popularity for weight management, but improper use can diminish their effectiveness. Dr. Meena T. Malhotra warns against five common mistakes users should avoid.
Novo Nordisk has announced the launch of a new high-dose GLP-1 injection for obesity treatment, priced $50 lower than its competitor Zepbound. This release comes amid increasing competition in the obesity medication market.
Novo Nordisk has announced new details regarding competition in the weight loss drug market following Eli Lilly's recent approval of a new obesity treatment. This comes as the obesity drug market experiences significant expansion with the introduction of new subscription models.